Real World Efficacy of Pembrolizumab of as a 1st Line Treatment in Metastatic Non-Small Cell Lung Cancer with PD-L1 High Expression

被引：0
|
作者：
Kasahara, K. [1 ]
Sone, T. [1 ]
Nishi, K. [2 ]
Shibata, K. [3 ]
Araya, T. [4 ]
Shirasaki, H. [5 ]
Yoneda, T. [6 ]
Kase, K. [7 ]
Nishikawa, S. [1 ]
Kimura, H. [1 ]
Tambo, Y. [1 ]
机构：
[1] Kanazawa Univ, Resp Med, Kanazawa, Ishikawa, Japan
[2] Ishikawa Prefectural Cent Hosp, Resp Med, Kanazawa, Ishikawa, Japan
[3] Kouseiren Takaoka Hosp, Med Oncol, Takaoka, Toyama, Japan
[4] Natl Hosp Org Kanazawa Med Ctr, Resp Med, Kanazawa, Ishikawa, Japan
[5] Fukui Ken Saiseikai Hosp, Resp Med, Fukui, Japan
[6] Komatsu Municipal Hosp, Resp Med, Komatsu, Japan
[7] Keiju Med Ctr, Resp Med, Nanao, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
Pembrolizumab; 1st line treatment; PD-L1 high expression;
D O I：
10.1016/j.jtho.2019.08.953
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.04-50
引用
收藏
页码：S460 / S460
页数：1
相关论文
共 50 条
  • [1] Real World Experience of 1st Line Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Ansel, S.
    Mcloone, P.
    Steele, N.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S926 - S926
  • [2] Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer
    Thu Oanh Dang
    Ogunniyi, Adebayo
    Barbee, Meagan S.
    Drilon, Alexander
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (01) : 13 - 20
  • [3] Real-World Efficacy of First-Line Pembrolizumab in Patients with Advanced PD-L1 High Non-Small Cell Lung Cancer in Argentina
    Kuzminin, A.
    Minatta, N.
    Bluthgen, M.
    Rizzo, M.
    Naveira, M.
    Wainsztein, V.
    Lupinacci, L.
    Rizzi, M.
    Faura, M.
    Perfetti, A.
    Recondo, G., Jr.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S589 - S590
  • [4] Real-world first-line treatment with pembrolizumab for non-small cell lung carcinoma with high PD-L1 expression: Updated analysis
    Ikezawa, Yasuyuki
    Morita, Ryo
    Mizugaki, Hidenori
    Tateishi, Kazunari
    Yokoo, Keiki
    Sumi, Toshiyuki
    Kikuchi, Hajime
    Kitamura, Yasuo
    Nakamura, Atsushi
    Kobayashi, Maki
    Aso, Mari
    Kimura, Nozomu
    Yoshiike, Fumiaki
    Megumi, Furuta
    Tanaka, Hisashi
    Sekikawa, Motoki
    Hachiya, Tsutomu
    Nakamura, Keiichi
    Hommura, Fumihiro
    Sukoh, Noriaki
    Ito, Kenichiro
    Kikuchi, Takashi
    Agatsuma, Toshihiko
    Yokouchi, Hiroshi
    CANCER MEDICINE, 2024, 13 (14):
  • [5] REAL WORLD OUTCOMES OF FIRST LINE PEMBROLIZUMAB MONOTHERAPY FOR ADVANCED PD-L1 POSITIVE NON-SMALL CELL LUNG CANCER
    Chu, R.
    Vegas, A.
    Gorry, C.
    Power, D.
    VALUE IN HEALTH, 2022, 25 (01) : S253 - S253
  • [6] Real-world data of first-line treatment with pembrolizumab for non-small cell lung cancer with high PD-L1 expression (HOT/NJLCG2001)
    Yokouchi, H.
    Mizugaki, H.
    Ikezawa, Y.
    Morita, R.
    Tateishi, K.
    Yokoo, K.
    Sumi, T.
    Kikuchi, H.
    Nakamura, A.
    Kobayashi, M.
    Aso, M.
    Tsukita, Y.
    Yoshiike, F.
    Furuta, M.
    Tanaka, H.
    Sekikawa, M.
    Hachiya, T.
    Nakamura, K.
    Kitamura, Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S1574 - S1574
  • [7] Impact of PD-L1 expression levels on the response to pembrolizumab in metastatic non-small cell lung cancer>
    Caldeira Marinho Matos, Joao Nunes
    Sousa, Sofia Rodrigues
    Figueiredo, Ana Maria
    Pego, Alice
    Barata, Fernando
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [8] Association between very high PD-l1 expression versus high PD-l1 expression in patients receiving pembrolizumab as firstline treatment for advanced non-small cell lung cancer
    Shah, Syed Mohsin Mahmood
    Marmarelis, Melina
    Mamtani, Ronac
    Hubbard, Rebecca
    Hennessy, Sean
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 96 - 97
  • [9] Real-World Efficacy of First-Line Pembrolizumab in Patients With Advanced or Recurrent Non-Small-Cell Lung Cancer and High PD-L1 Tumor Expression
    Tambo, Yuichi
    Sone, Takashi
    Shibata, Kazuhiko
    Nishi, Kouichi
    Shirasaki, Hiroki
    Yoneda, Taro
    Araya, Tomoyuki
    Kase, Kazumasa
    Nishikawa, Shingo
    Kimura, Hideharu
    Kasahara, Kazuo
    CLINICAL LUNG CANCER, 2020, 21 (05) : E366 - E379
  • [10] First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
    Zhou, Yixin
    Lin, Zuan
    Zhang, Xuanye
    Chen, Chen
    Zhao, Hongyun
    Hong, Shaodong
    Zhang, Li
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
12345